This is a working overview of heptapeptide, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-13. Anything still debated is marked as such rather than presented as settled.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. Its design combines the ACTH(4-7) core fragment with a C-terminal Pro-Gly-Pro extension, a modification intended to improve stability and prolong activity. The molecule is hydrophilic, carries no lipid chains or glycosylation, and has a theoretical mass just over 810 daltons in its free form. All seven residues are proteinogenic amino acids, so no non-natural building blocks appear in the backbone. A free N-terminal methionine and C-terminal proline define the unmodified parent peptide.
The compound was developed during the 1980s at the Institute of Molecular Genetics in Moscow as part of research on fragments of adrenocorticotropic hormone. Early work examined short ACTH-derived sequences that retained neurotrophic effects while lacking the endocrine activity of the full hormone. Semax entered clinical use in Russia during the 1990s, where it received registration for several neurological indications. Outside that region it remained primarily a laboratory research material rather than an approved therapeutic. English-language literature on it grew more slowly and frequently cited the original Russian studies.
Terminology around the compound varies by source. It appears in catalogues and papers as Semax, as the heptapeptide ACTH(4-7)-Pro-Gly-Pro, and under various alphanumeric laboratory codes used by individual suppliers. These names refer to the same sequence but may imply different salt forms, purity grades, or counter-ions. Peptide databases usually list the free base mass, while product descriptions sometimes report acetate or trifluoroacetate salts with a different formula weight. Because naming conventions for research peptides are not standardised across vendors, checking the declared sequence and measured mass is more reliable than relying on a trade name alone.
Laboratory descriptions of the material are consistent across suppliers. It appears as a white to off-white lyophilized powder that dissolves readily in water and in polar organic solvents such as dimethyl sulfoxide. Aqueous solutions are clear and colorless at low concentrations. Because the peptide contains methionine, oxidation at the sulfur atom is a recognized degradation pathway, and handling notes usually call for protected, desiccated storage. Reported purity for research-grade lots is generally above 95 percent as measured by reversed-phase high-performance liquid chromatography.
The compound is registered in Russia as a pharmaceutical product, most commonly formulated as a nasal solution, and has been used in that setting since the 1990s. Outside that jurisdiction it is generally handled as a research chemical rather than an approved medicine. Regulatory status therefore differs sharply between countries, and material sold internationally may not correspond to the Russian pharmaceutical formulation. Documentation with commercial samples is typically limited to a certificate of analysis covering purity and identity, not clinical status or local legal classification.
Semax is a synthetic heptapeptide with the sequence Met-Glu-His-Phe-Pro-Gly-Pro. It corresponds to the ACTH(4-7) fragment extended at the C-terminus by a Pro-Gly-Pro tripeptide, an addition intended to slow enzymatic breakdown. The molecular formula is C37H51N9O10S and the molecular mass is approximately 814 daltons. In the literature it is often described as an ACTH(4-10) analog, although that label reflects a naming convention as much as a precise structural relationship. The compound was developed in Russia and remains most closely associated with that research tradition.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic heptapeptide | ACTH(4-7) analogue |
| Sequence | Met-Glu-His-Phe-Pro-Gly-Pro | Free N terminus, unmodified side chains |
| Molecular weight | 813.9 Da | Free base; salt forms differ |
| Appearance | White to off-white powder | Lyophilised solid |
| Solubility | Freely soluble in water | Hydrophilic; polar solvents preferred |
=== Autism spectrum disorder === Unlike ADHD, which significantly increases the risk of substance use disorder, autism spectrum disorder has the opposite effect of significantly reducing the risk of substance use. This is because introversion, inhibition and lack of sensation seeking personality traits, which are typical of autism spectrum disorder, protect against substance use and thus substance use levels are low in individuals who are on the autism spectrum. However, certain forms of substance use disorders, especially alcohol use disorder, can cause or worsen certain neuropsychological symptoms which are common to autism spectrum disorder. This includes impaired social skills due to the neurotoxic effects of alcohol on the brain, especially in the prefrontal cortex area of the brain. The social skills that are impaired by alcohol use disorder include impairments in perceiving facial emotions, prosody perception problems and theory of mind deficits; the ability to understand humour is also impaired in people who consume excessive amounts of alcohol.
=== Clinical Services === BRT's Clinical Services division is licensed by the State of Maryland Department of Health and Mental Hygiene Archived 2006-01-30 at the Wayback Machine for Molecular Biology and Molecular Genetics and is registered under the US Department of Health and Human Services' Clinical Laboratory Improvement Amendments. Test offerings include Tuberculosis testing and Bone Marrow Engraftment (chimerism) monitoring. BRT’s tuberculosis (TB) testing is performed using the Interferon-gamma release assay T-SPOT.TB. This assay is recognized by the Centers for Disease Control and Prevention as a special TB blood test with an accuracy of diagnosing active TB >80%. Bone Marrow Engraftment monitoring assesses the relative ratio of donor and recipient cell populations in the post-transplant peripheral blood or bone marrow of the patient. BRT performs this test using STR analysis, the current "gold standard," yielding a sensitivity of 95–98%.
== Contents == A 1958 source describes Dover's Powder as follows: "Powder of Ipecacuanha and Opium (B.P., Egyp. P., Ind. P.). Pulv. Ipecac. et Opii; Ipecac and Opium Powder (U.S.N.F.); Dover's Powder; Compound Ipecacuanha Powder. Prepared ipecacuanha, 10 g., powdered opium 10 g., lactose 80 g. It contains 1% of anhydrous morphine. Dose: 320 to 640 mg. (5 to 10 grains). Many foreign pharmacies include a similar powder, sometimes with potassium sulphate or with equal parts of potassium nitrate and potassium sulphate in place of lactose; max. single dose 1 to 1.5 g. and max. in 24 hours 4 to 6 g."
Because failure to properly carry out any one of the components can severely affect the usefulness of using drug concentrations to optimize therapy, an organized approach to the overall process is critical.
Sources: en.wikipedia.org
Jerden later said that he was told Staley felt animosity toward him dating back to the Dirt sessions due to Jerden repeatedly recommending to Staley that he get sober. Jerden said, "Apparently he got all mad at me [during the Dirt sessions] ... And what's my job as a producer? To produce a record. I'm not getting paid to be Layne's friend". Staley was not the only one who went through heavy drug use; drummer Sean Kinney and bassist Mike Starr were both struggling with alcoholism, while the latter was also addicted to heroin. Jerden got the album's famous guitar tone by blending three different amps – a Bogner Fish preamp for the low end, a Bogner Ecstacy for the mid frequencies, and a Rockman Headphone amp for the high frequencies.
== Receptor regulation == Cells can increase (upregulate) or decrease (downregulate) the number of receptors to a given hormone or neurotransmitter to alter their sensitivity to different molecules. This is a locally acting feedback mechanism.
The AlphaFold Protein Structure Database (AlphaFold DB) is a collaborative project with Google DeepMind to make predicted protein structures from the AlphaFold AI system freely available to the scientific community. The first release of the database was in 2021; as of 2024, AlphaFold DB provides access to over 214 million protein structures. National Center for Biotechnology Information (NCBI), United States National Library of Medicine National Institute of Genetics (DNA Data Bank of Japan) Swiss Institute of Bioinformatics (SIB: Expasy) Australia Bioinformatics Resource BIG Data Center (National Genomics Data Center), Beijing Institute of Genomics, Chinese Academy of Sciences Alternative splicing and transcript diversity database BioJS - open-source project for bioinformatics data on the web BioSamples European Molecular Biology Organization European Nucleotide Archive
== Development and release == Counter-Strike: Source is a remake of the original Counter-Strike built on Valve’s Source engine and the third major installment in the Counter-Strike series. Announced on May 12, 2004 during E3 presentation as the multiplayer component of Half-Life 2, it became the first Source engine game released by Valve Software, arriving on Steam for Windows on October 7, 2004, more than a month before Half-Life 2 itself. The first public beta became available on August 11, 2004 through the Valve Cyber Café Program, followed by a wider beta release on August 18 for owners of Counter-Strike: Condition Zero and users who received Half-Life 2 vouchers bundled with select ATI Radeon video cards. The game was later included in Half-Life 2 retail bundles released on November 16, 2004. Development of Counter-Strike: Source began at Valve in January 2004, with contributions from the original Counter-Strike creators Minh Le and Jess Cliffe, as well as members of the Day of Defeat team. The main goal of the developers was to transfer Counter-Strike to the Source engine without altering the core gameplay mechanics. To achieve this, the designers took the Counter-Strike 1.1 build, stripped it down to its bare essentials, and rebuilt it piece by piece in the Source engine. They later incorporated features introduced in subsequent Counter-Strike releases, including version 1.6 and Condition Zero.
Several degradation processes occur, some during cycling, some during storage, and some all the time: Degradation is strongly temperature-dependent: degradation at room temperature is minimal but increases for batteries stored or used in high temperature (usually > 35 °C) or low temperature (usually < 5 °C) environments. Also, battery life in room temperature is maximal. High charge levels also hasten capacity loss. Frequent charge to > 90% and discharge to < 10% may also hasten capacity loss. Keeping the li-ion battery status to about 60% to 80% can reduce the capacity loss. In a study, scientists provided 3D imaging and model analysis to reveal main causes, mechanics, and potential mitigations of the problematic degradation of the batteries over charge cycles. They found "[p]article cracking increases and contact loss between particles and carbon-binder domain are observed to correlate with the cell degradation" and indicates that "the reaction heterogeneity within the thick cathode caused by the unbalanced electron conduction is the main cause of the battery degradation over cycling". The most common degradation mechanisms include:
Sources: en.wikipedia.org
It is a synthetic seven-amino-acid peptide built from the ACTH(4-7) sequence plus a Pro-Gly-Pro tail. It belongs to the family of short ACTH fragments studied for nervous-system effects. Its backbone contains only standard amino acids.
It contains the 4-7 fragment of adrenocorticotropic hormone extended at the C terminus. That truncation removes the region associated with steroidogenic activity. The design intent was to keep neurotrophic properties while avoiding full hormonal effects.
No natural source of the intact heptapeptide is known. It is produced by solid-phase peptide synthesis. Some related ACTH fragments arise as hormone processing products, but the Pro-Gly-Pro extension is a designed addition rather than a natural sequence.
It is registered as a pharmaceutical product in Russia, where it is typically supplied as a nasal solution. In most other countries it is not an approved drug and is traded as a research chemical instead. Approval status depends entirely on the jurisdiction involved.